Truist raised the firm’s price target on Tenet Healthcare (THC) to $190 from $180 and keeps a Buy rating on the shares. The firm is bullish after the company’s “strong” Q3 results featuring top and bottom-line beats that were fueled by strong Hospital volumes and brisk revenue per case growth, the analyst tells investors in a research note. The initial FY25 commentary was also solid, with attractive trends expected to more than offset some normalizing factors, the firm added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $177 from $168 at Cantor Fitzgerald
- Tenet Healthcare price target raised to $217 from $197 at UBS
- Tenet Healthcare price target raised to $183 from $174 at RBC Capital
- Tenet Healthcare Reports Strong Q3 Results and Raises Outlook
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz